Incretin Receptor Pharmacology: How GLP-1R, GIPR and GCGR Signal

Three receptors sit at the centre of a large and fast-moving literature: the GLP-1 receptor, the GIP receptor and the glucagon receptor. Incretin receptor pharmacology is the study of how peptide ligands bind and switch on these receptors, which signalling routes follow, and how engineered sequences can be tuned to act at one, two or all three. For assay scientists and lab managers setting up receptor panels, the details decide which experiments are worth running and how their numbers should be read. This article stays at the level of receptors, cell systems and in-vitro methods throughout.

Incretin receptor pharmacology starts with class B1 architecture

All three receptors belong to class B1 of the G protein-coupled receptor superfamily, sometimes called the secretin family. Members of this class share a two-part design that sets them apart from the more familiar class A receptors:

• A sizeable extracellular domain at the N-terminus of the receptor, stabilised by three conserved disulfide bonds, which forms a groove that holds the ligand’s C-terminal region.
• A seven-helix transmembrane core, with a deep, fairly polar pocket that receives the ligand’s N-terminal residues.

Their natural ligands are also related. GLP-1 and glucagon are both cut from the same precursor, proglucagon, while GIP comes from its own gene. All three peptides belong to the glucagon superfamily and are most alike near their N-termini, which is exactly the region that drives receptor activation. That shared ancestry is why a single designed sequence can be made to activate more than one of these receptors.

How a peptide switches a class B1 receptor on

Activation is usually described as a two-step process. First, the helical C-terminal half of the peptide docks into the extracellular domain. This step supplies most of the binding energy but does not activate anything. Second, with the ligand tethered close by, its first several residues slide into the transmembrane pocket.

That insertion is what drives the conformational change. The sixth transmembrane helix contains a conserved Pro-x-x-Gly motif that allows it to kink sharply; as the ligand settles, the lower part of the helix swings outward and opens a cavity on the inside of the cell where the G protein binds. Cryo-electron microscopy structures of each of the three receptors, bound to an agonist and to Gs, have now been published, and they show these poses directly.

Two practical lessons follow for anyone working with these ligands in vitro:

1. N-terminal truncation separates binding from activation. Removing the first few residues can leave substantial affinity while abolishing agonism. The classical GLP-1 receptor antagonist exendin(9-39) was arrived at by exactly this logic.
2. Affinity and efficacy can be tuned somewhat independently. Because the two halves of the ligand do different jobs, sequence changes in one half can shift binding without much effect on activation, and vice versa.

The three receptors compared

Both GLP-1 and GIP are rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), which removes the first two residues. Since those residues are needed for activation, the truncated products lose agonist activity, a point that matters for any assay run in serum or tissue preparations containing the enzyme.

The GIP receptor deserves a note of caution. Both activating and blocking it have been reported to produce similar outcomes in animal studies, and no single explanation has been accepted. One proposal is that prolonged agonism desensitises the receptor so thoroughly that it behaves like blockade. For a lab, the message is that the direction of a GIPR effect should be measured in the system being used rather than assumed.

Beyond cAMP: coupling, arrestin and signalling bias

All three receptors couple mainly through Gs, raising cAMP and activating protein kinase A. A cAMP concentration-response curve is therefore the standard first measurement. It is far from the whole story.

• Gq coupling. In some cell backgrounds, and especially at high receptor expression, the GLP-1 receptor also signals through Gq, producing inositol phosphate and calcium responses.
• Arrestin recruitment. After receptor kinases phosphorylate the C-terminal tail, beta-arrestins bind and promote desensitisation and internalisation.
• ERK1/2 phosphorylation. Fed by more than one upstream route, so poor at discriminating between ligands on its own.
• Internalisation and recycling. Tracked by surface labelling or imaging; they shape responses to sustained rather than brief exposure.

Two terms describe how multi-receptor ligands differ from one another. Imbalance means unequal potency across the receptors a molecule targets, often by design. Bias means favouring one pathway over another at the same receptor, typically cAMP over arrestin. Bias is a ratio of ratios: a ligand’s pathway preference is always expressed relative to a reference agonist, and it cannot be read from any single assay.

Stability modifications and how they show up in vitro

Most engineered ligands for these receptors carry changes meant to survive DPP-4 and other proteases. Each leaves a mark on in-vitro data:

• Position-2 substitution, commonly with aminoisobutyric acid (Aib), blocks DPP-4 and stiffens the backbone, which can nudge potency up or down depending on the receptor.
• Fatty diacid acylation through a linker on a lysine side chain lets the peptide bind albumin reversibly. In an assay buffer containing albumin, part of the ligand is bound and unavailable, so the measured EC50 moves to higher concentrations.
• Helix stabilisation with lactam bridges or helix-favouring residues improves protease resistance and can sharpen selectivity by holding the bound shape.
• Chimeric design borrows recognition features from two or three native hormones and combines them in one sequence, then adjusts single positions to reach a target potency ratio across receptors.

Building a receptor panel that gives comparable numbers

Labs profiling several ligands across all three receptors run a lot of plates, and the value of the data depends on keeping conditions constant. The recurring methods:

• Competition binding with a radiolabelled or fluorescent tracer gives Ki; fluorescence and BRET formats can also report association and dissociation rates. Our overview of binding assay formats compares them.
• cAMP accumulation by HTRF, luciferase biosensor or similar gives EC50 and Emax, but is highly sensitive to receptor reserve: a partial agonist can look full in a high-expressing line.
• GTP-gamma-S binding measures G protein activation before amplification, so it sits closer to intrinsic efficacy.
• Arrestin recruitment by enzyme complementation or BRET is required for any claim about bias.

Four conditions should be fixed and reported for every plate: receptor density in a defined cell line, the reference agonist, whether albumin is in the buffer, and whether the receptor is human or rodent. Changing any one can move potency by more than the differences a study is trying to detect. For definitions of the potency terms themselves, see Ki, IC50 and EC50 explained.

Checking the ligand before trusting the curve

Receptor data are only as good as the peptide in the well. Long, often lipidated sequences need more checking than short ones:

1. Reversed-phase HPLC purity with the gradient and column stated, since near-identical deletion sequences can merge under a shallow gradient.
2. Mass confirmation against the calculated value, remembering to include any lipid and linker in the arithmetic.
3. Net peptide content, because counter-ions and water mean gross weight overstates peptide mass enough to shift an EC50.
4. Aggregation state by size-exclusion chromatography or light scattering; amphipathic sequences self-associate, and a cell assay will simply return a misleading value.

Stored stocks should be kept cold, divided into single-use aliquots, and protected from light, with stability confirmed rather than assumed. Our note on half-life and analog modifications covers the sequence changes above in more depth.

This article covers receptor pharmacology and in-vitro methods from the published literature only. It makes no statement about any product, and nothing here concerns use in humans or animals.